Business
Board Changes
Board Changes.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 6256Z N4 Pharma PLC 21 May 2019 \n\n21 May 2019\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nBoard Changes\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, is pleased to announce the appointment of Dr John Chiplin as Non-Executive Chairman of the Company, and the appointment of Dr Chris Britten as a Non-Executive Director of the Company (the \"Appointments\"). In addition, Paul Titley has decided to step down from the board for personal reasons and Dr David Templeton, formerly Chairman, will now serve as a part-time Executive Director in order to manage the technical aspects of the Company's Nuvec® programme. All board changes are effective immediately. The Board would like to take this opportunity to thank Paul Titley for his valuable contribution to the Company over the last two years.\n \nDr John Chiplin has significant operational, investment and transaction experience in the life science and technology industries. Between 1995 and 2014, Dr Chiplin served as CEO of three leading publicly listed software, biotechnology and cancer immunotherapy companies in the US. Based in London, Dr Chiplin's current board roles include Adalta, Cynata, Regeneus and Scancell Holdings plc (AIM: SCLP). He is also Managing Director of Newstar Ventures Ltd, an international private equity firm focused on emerging companies.\n \nDr Chris Britten is an experienced pharmaceutical executive and is currently Head of M&A at Neuraxpharm, a privately-owned European CNS specialty pharmaceutical company. He has over 20 years' experience in R&D, corporate development and investment banking. Previous roles include Global Head of M&A at Sandoz (Munich), Managing Director at Torreya Partners (London), Head of Business Development at Sanofi Pasteur MSD (Lyon) and Director, Life Sciences at Deloitte Corporate Finance (London). Chris also spent many years at GSK in both drug discovery and corporate development. \n \nOption Grant\n \nIn conjunction with the Appointments, Dr John Chiplin and Dr Chris Britten have each been granted 717,143 options over new ordinary shares in the Company (\"Options\"). The Options represent approximately 1.41 per cent. of the Company's existing i...